Logo

BYSI

BeyondSpring Inc.

BYSI

BeyondSpring Inc. • NASDAQ
$2.12 ▲ 1.44% (+0.03)
Market Cap $85.50 M
52w High $3.44
52w Low $0.98
Dividend Yield 0%
P/E -11.16
Volume 19.98K
Outstanding Shares 40.33M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.769M ▼ $-1.54M ▲ 0% $-0.04 ▲ $-1.696M ▲
Q2-2025 $0 $1.949M ▼ $-1.806M ▼ 0% $-0.045 ▼ $-1.867M ▲
Q1-2025 $0 $2.61M ▲ $4.477M ▲ 0% $0.11 ▲ $-2.53M ▼
Q4-2024 $0 ▼ $1.7M ▼ $-1.729M ▲ 0% ▲ $0.016 ▲ $-1.68M ▲
Q2-2024 $500K $4.211M $-3.631M -726.2% $-0.093 $-3.635M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $12.624M ▲ $29.484M ▼ $49.294M ▲ $-31.775M ▼
Q2-2025 $9.544M ▲ $31.043M ▼ $48.588M ▼ $-30.216M ▼
Q1-2025 $8.527M ▲ $37.104M ▲ $49.771M ▲ $-28.309M ▲
Q4-2024 $2.922M $34.315M $48.6M $-32.9M
Q3-2024 $2.922M $34.315M $48.6M $-32.9M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.784M ▲ $-4.292M ▲ $1.616M ▼ $279.478K ▲ $2.939M ▼ $-4.292M ▲
Q2-2025 $-1.806M ▲ $-5.874M ▼ $10.85M ▲ $0 $4.969M ▲ $-5.874M ▼
Q1-2025 $-2.509M ▼ $-4.452M ▼ $6.304M ▲ $0 $-35.098M ▼ $-4.502M ▼
Q4-2024 $0 ▲ $0 $0 $0 $0 $0
Q2-2024 $-3.631M $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement BeyondSpring is still a pure research and development story, with no product revenue over the past several years. Its costs are mainly tied to R&D and overhead, which together produce ongoing losses. The encouraging side is that these losses have been shrinking, suggesting tighter cost control or a scaling back of activity. However, the business remains structurally unprofitable until at least one drug is approved and commercialized, so continued losses should be expected in the near term.

Balance Sheet

Balance Sheet The company runs a very lean balance sheet, with a small base of assets mostly in the form of cash and equivalents. It carries no traditional debt, which reduces financial strain from interest payments. The concern is that equity has recently turned negative, meaning obligations now exceed assets. This points to financial fragility and underscores how dependent the company is on future funding or partnerships to keep advancing its pipeline.

Cash Flow

Cash Flow Cash is consistently flowing out of the business, mainly to fund research, clinical trials, and operations. There is no offsetting cash coming in from product sales, so the company is drawing down its limited cash resources over time. Capital spending on physical assets is minimal, which is typical for a biotech. The key issue is that the current cash burn, even if reduced compared with earlier years, must be matched with fresh capital if development is to continue at pace.

Competitive Edge

Competitive Edge BeyondSpring’s competitive edge rests on a focused oncology strategy built around a novel lead drug, Plinabulin. Its approach to both cancer treatment and prevention of chemotherapy-related complications is differentiated and protected by patents, which can provide a defensible niche if clinical and regulatory outcomes are favorable. At the same time, it operates in a highly competitive field dominated by much larger pharmaceutical companies with deeper pockets, broader pipelines, and established commercial infrastructures. The company also depends heavily on the success of a small number of key programs, which concentrates risk.

Innovation and R&D

Innovation and R&D Innovation is the core strength here. Plinabulin has a distinctive mechanism that targets both tumor control and protection of the immune system during chemotherapy, which is not common among existing treatments. Beyond this, the company is building a broader early-stage pipeline and has exposure to targeted protein degradation through its SEED Therapeutics subsidiary, a cutting-edge area in drug discovery. These efforts show scientific ambition and potential for long-term value creation, but many of the projects are still early, with significant scientific, regulatory, and execution risk ahead before they can translate into commercial success.

Summary

BeyondSpring is a classic early-stage biotech: science-rich but revenue-poor. Financially, it runs with small resources, ongoing losses, and negative equity, balanced by the absence of traditional debt. Its future depends on two main pillars: successful clinical and regulatory progress for Plinabulin and other pipeline assets, and its ability to secure enough funding or partnerships to support that progress. The company’s strength lies in its innovative oncology platform and intellectual property, while its key vulnerabilities are financial fragility, reliance on a few lead programs, and exposure to the uncertainties inherent in drug development.